In this issue:
Semaglutide in obesity-related HF and type 2 diabetes
Semaglutide in obesity-related HFPEF
Age-specific mortality trends in HF over 25 years
Long-term impact of home-based monitoring after acute decompensated HF
Impact of race on benefit of RAS blockade in HF
Empagliflozin vs. dapagliflozin in HF
HF in remote Central Australia: Indigenous and non-Indigenous patients
Kidney outcomes after hospitalisation for HF
Atrial shunt device effects on cardiac structure and function in HFPEF
AF ablation in HFREF vs. HFPEF
Please login below to download this issue (PDF)